Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer ’s Disease

ConclusionThe model predicted long-term benefits of aducanumab treatment in patients with MCI due to AD and mild AD dementia and their caregivers. The predicted outcomes provide a foundation for healthcare decision-makers and policymakers to understand the potential clinical and socioeconomic value of aducanumab.

http://link.springer.com/10.1007/s40120-021-00273-0

Source: Neurology and Therapy - August 23, 2021 Category: Neurology Source Type: research